An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management by Davies, J. & Ingham, A.
International Journal of Pharmaceutics 487 (2015) 101–109An in-vitro–in-vivo model for the transdermal delivery of
cholecalciferol for the purposes of rodent management
J. Davies a, A. Inghamb,*
a School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
b School of Pharmacy, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
A R T I C L E I N F O
Article history:
Received 15 November 2014
Received in revised form 24 March 2015
Accepted 27 March 2015
Available online 30 March 2015
Chemical compounds studied in this article:
Cholecalciferol (PubChem CID: 5280795)
Keywords:
Cholecalciferol
Transdermal
Rodenticide
BPR
Regulation No. 528/2012
Efﬁcacy
A B S T R A C T
The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to
anticoagulant rodenticides which differs in both active ingredient and in the method of dosing.
Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of
penetration enhancing formulations in two in-vitro models and ﬁnally in-vivo.
A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol
was judged as ‘sufﬁciently effective’ in line with the European Union’s Biocidal Products Regulation
(No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in
64.4 h (22 h).
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In mammals, cholecalciferol is photosynthesised in the plasma
membrane of the dermis when 7-dehydrocholestrol is exposed to
wavelengths of light between 290 and 315 nm (Holick et al., 1995;
MacLaughlin et al., 1982). Once produced, cholecalciferol is
metabolised in the liver and kidneys to form 1,25-dihydroxyvita-
min D (Holick and Garabedian, 2006; Holick, 1989, 2009) which is
used in calcium homeostasis (Holick, 1989).
Due to their small size, mammals such as rats, mice and
rabbits are found to have relatively low tolerance to doses of
cholecalciferol leading to consideration of the potential rodenti-
cidal uses (Agnew, 2010, 2011; Eason, 1991, 1993; Marshall, 1984).
Cholecalciferol has several potential advantages over current
rodenticides including a reduced risk to non-target species, such as
birds, who possess a relatively high tolerance to the compound
(Erickson and Urban, 2004; Marshall, 1984). In regards to human
safety, deﬁciency in the compound is the prevailing problem with
one billion people worldwide thought to be deﬁcient (Holick,
2007); deﬁciency can lead to rickets in children and osteoporosis in
adults (Feldman and Malloy, 2004; Holick, 2003, 2006).* Corresponding author. +44 (0) 121 204 3913.
E-mail address: a.j.ingham@aston.ac.uk (A. Ingham).
http://dx.doi.org/10.1016/j.ijpharm.2015.03.055
0378-5173/ã 2015 Published by Elsevier B.V.Anticoagulant poisons, such as warfarin, are the most
commonly used method of rodent control; their action inhibits
the body’s natural blood clotting pathways. Prolonged oral use of a
rodenticide causes natural selection of warfarin resistant rats
(Boyle, 1960; Lasseur et al., 2005; Lund, 1964; Pelz et al., 1995;
Tanikawa et al., 2006; Thijssen, 1995) which has spawned a more
potent ‘second generation’ of anticoagulants including bromadio-
lone and difenacoum; however, resistance to these compounds has
now been reported (Endepols et al., 2012; Greaves et al., 1982;
Rowe et al., 1981).
A behavioural resistance has also been observed when using
anticoagulant baits (Brunton et al., 1993; Macdonald et al., 1999).
This behavioural resistance stems from the neophobic nature of
many pest species, speciﬁcally, a hesitancy to approach unfamiliar
foods and objects (Barnett,1958; Beck et al.,1988; Sunnucks,1998).
This behaviour decreases the effectiveness of bait approaches
(Brunton et al., 1993; Quy et al., 1992).
There is a need for an alternative to rodent control performed
with anticoagulant bait, which differs both in active ingredient and
manner of delivery. Cholecalciferol, as well as being a suitable
rodenticide, can be delivered via a transdermal route (Agnew,
2010, 2011). Here we present two in-vitro models for the delivery of
cholecalciferol through a synthetic membrane and the
corresponding in-vivo data. The in-vitro models have been used
to determine an optimum formulation, comprising of active
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promotes enhanced delivery of cholecalciferol through the dermis.
The legislative guidance on biocidal products, including
rodenticides, is given in Regulation No. 528/2012 (concerning
the making available on the market and use of biocidal products)
(European Commission, 2012). In order for a rodenticide to be
approved as a biocidal product it must ﬁrst be proven ‘sufﬁciently
effective’. The in-vivo investigations required by law are provided
under speciﬁc guidance. To prevent replication of in-vivo
investigations it was logical to use the guidelines suggested by
the Regulations in both data generation and model development.
2. Materials and methods
2.1. Materials
European pharmacopoeia grade cholecalciferol was purchased
from Fagron UK Ltd. (Newcastle on Tyne, UK). Penetration
enhancers ethanol, oleic acid and dimethyl sulfoxide (DMSO)
were purchased from Fisher Scientiﬁc UK Ltd. (Loughborough, UK),
2-pyrrolidone was purchased from Sigma–Aldrich Co. (St. Louis,
MO, USA); all were laboratory reagent grade. Methyl cellulose
(Fisher Scientiﬁc UK Ltd. (Loughborough, UK)) and polyethylene
glycol mw200 (PEG 200) (Sigma–Aldrich Co. (St. Louis, MO, USA))
were used as viscosity modifying agents. The receiver phase for the
in-vitro studies was composed of ethanol (Fisher Scientiﬁc UK Ltd.
(Loughborough, UK)), polyethylene glycol mw200 (Sigma–Aldrich
Co. (St. Louis, MO, USA)) and deionised water. Regenerated
cellulose dialysis membrane (visking tubing, Fisher Scientiﬁc UK
Ltd. (Loughborough, UK)) was used for the synthetic membrane
(Corrigan et al., 1980; Haigh and Smith, 1994; Wang et al., 2006;
Wissing and Müller, 2002).
2.2. Methods
2.2.1. Permeation studies
2.2.1.1. Cellulose tubing in-vitro model. Dialysis tubing was cut into
strips and sealed on one side. For each formulation 1 ml was
dispensed into the dialysis tubing and placed in a 50 ml centrifuge
tube containing 45 ml of receiver phase. An aqueous ethanol
(10/90 (v/v)) receiver phase containing 6% (v/v) PEG 200 was
used as cholecalciferol is practically insoluble in water
(British Pharmacopoeia, 2013). Sampling of the receiver phase
was performed every hour for the ﬁrst 4 h then every 2 h for a total
experiment time of 8 h. At each sampling point 5 ml of the receiver
phase was removed and replaced with stock receiver phase. Of the
5 ml, 200 ml was extracted and diluted before analysis. The
temperature of the receiver phase was maintained at
26 C  2 C by the immersion of the centrifuge tubes in a
heated water bath. Three replicates were employed for each
formulation.
2.2.1.2. Diffusion cell in-vitro model. The membrane was cut into
5  5 cm squares and placed between the donor and receiver
chambers of a static diffusion cell (Ingham Group, Aston University,
UK). For each formulation 15 ml of receiver solution was placed in
to the receiver chamber while 5 ml of the assay was dispensed into
the donor. An aqueous ethanol (10/90 (v/v)) receiver phase
containing 6% (v/v) PEG 200 was used. Sampling of the receiver
phase was performed every hour for the ﬁrst 5 h then every 2 h for
a total experiment time of 9 h. At each sampling point 5 ml of the
receiver phase was removed and replaced with stock receiver
phase. Of the 5 ml, 200 ml was extracted and diluted before
analysis. The temperature of the receiver phase was maintained at
37 C  2 C with a heated stirring plate.2.2.1.3. Formulations. Two batches of ﬁve formulations were
tested with the cellulose tubing model; the ﬁrst set of ﬁve
formulations investigated a range of chemical penetration
enhancers at various concentrations to determine the optimum
chemical penetration enhancer. The second batch of ﬁve
formulations investigated a range of DMSO/ethanol co-solvents.
Two batches of formulations were tested with the diffusion cell
model; the ﬁrst set investigated a range of penetration enhancers
at various concentrations to determine the optimum chemical
penetration enhancer. The second batch varied in cholecalciferol
concentration.
2.2.1.4. Chemical penetration enhancement. Chemical penetration
enhancers (Stoughton and Fritsch, 1964) have been shown to
increase the penetration of compounds such as antiviral agents,
steroids and antibiotics (Williams and Barry, 2012). DMSO and the
sulfoxide family damage the stratum corneum promoting
intercellular passage of the penetrant. Organic solvents, such as
ethanol, increase penetration by extracting the lipids from the
horny layer. Fatty acids such as oleic acid have also been shown to
improve dermal penetration (Larrucea et al., 2001; Meshulam
et al., 1993; Moreira et al., 2010) by creating reservoirs in the
stratum corneum in which the penetrant can move through.
DMSO, ethanol, water, 2-pyrrolidone and oleic acid were chosen as
the potential penetration enhancers.
2.2.1.5. Membrane preparation. Cellulose membranes were
cleaned before use in 1 l of cleaning solution consisting of 2%
(w/v) sodium bicarbonate (Sigma–Aldrich Co. (St. Louis, MO, USA))
and 1 mM of ethylenediaminetetraacetic acid (EDTA) in distilled
water. The cellulose membrane was placed in the solution while
the temperature was brought up to 80 C; the solution was then
maintained at 80 C for 30 min. After cleaning, the membranes
were rinsed thoroughly with distilled water and kept in a bath of
distilled water for a maximum of 5 days prior to use in accordance
with the manufacturer’s guidelines (Medicell International Ltd.,
2004).
2.2.1.6. Data analysis. For each formulation used in the in-vitro
study, the drug ﬂux (Js) was calculated. This value was obtained
with Fick’s ﬁrst law of diffusion after plotting the cumulative drug
amount in the receiver chamber against time (Martin and
Bustamante, 1993):
Js ¼
1
A
dM
dt
 
ss
where A refers to the cross sectional area (cm2), and (dM/dt)ss is the
rate of drug permutation across the membrane over time (mg/h) at
steady state. By plotting the cumulative amount of drug received in
the receiver chamber against time (dM/dt)ss (the gradient) can be
calculated at steady state (i.e. when the relationship is linear). A
diffusion area of 40 cm2 was used for the cellulose tubing
calculations while an area of 2.54 cm2 was used for the diffusion
cell method.
2.2.1.7. HPLC analysis. Quantitative analysis of all cholecalciferol
assays was performed with high performance liquid
chromatography (Prominence Modular HPLC (Shimadzu
Corporation, Japan)) using a UV diode array. The speciﬁc
wavelength of detection was 265 nm. A Luna 3m NH2 100A
column (Phenomenex, Cheshire, UK), dimensions: 150  4.6 mm
was used with a NH2 3 mm ID security guard and holder. The total
ﬂow rate was 2 ml/min and the run time was 6 min. The mobile
phase consisted of hexane/isopropanol (HPLC grade). During the
ﬁrst 3 min of the run a gradient ratio of 99/1–50/50 (v/v) hexane/
isopropanol was used, a ratio of 99/1 (v/v) hexane/isopropanol was
Fig. 1. Cholecalciferol permeation proﬁles obtained with the cellulose tubing in-
vitro model. All formulations contained 10% (w/v) cholecalciferol released from a
volume of 1 ml. Mean values  SD (n = 3).
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cholecalciferol was calculated for each assay by using an
equation derived from the slope of the standard curve prepared
for cholecalciferol (r2 = 0.999) at 265 nm.
2.2.2. In-vivo studies
2.2.2.1. Animal husbandry. All in-vivo investigations were
undertaken at Cellvax Pharma (Paris, France). The experimental
protocols were approved by the Ministere de L’enseignement
Superieur de la Recherche (ComEth Anses/ENVA/UPEC 16).
Male Sprague-Dawley rats (Harlan, France) aged between
7–10 weeks were employed in the protocol. Each rat weighed
between 250 and 350 g and was of SOPF (Speciﬁc and
Opportunistic Pathogen Free) status. Animals were housed
in polyethylene cages in a climate and light controlled
environment. Hours of lighting were between 7:00 and 19:00,
the temperature and humidity was maintained at 21 1 C and 70%
RH, respectively. Animals had a constant supply of food and water.
In the case of the initial chemical penetration enhancement
study the animals were housed singularly, in the efﬁcacy screening
study animals were housed in groups of twos and threes, fur
shaving was employed to identify each animal only. All animals
were acclimatised to the laboratory for at least one week prior to
the start of the experiment.
2.2.2.2. Distress scoring. In order to assess the effect of the
formulation on the animals, and to quantify any distress or
suffering, an assessment of distress was made 2–3 times a day
using a distress scoring chart. The chart considered ﬁve key areas in
which distress could be displayed, these areas are: general
appearance, appearance of application site, natural behaviour,
provoked behaviour and food and water intake. Each of these areas
was given a mark out of 3 providing for a maximum distress of 15. A
score of 0 would suggest the formulation had no effect. A score of
1–5 is indicative of minor changes in behaviour or appearance; a
score of 5–10 is suggestive of moderate changes while a score of
over 10 suggests signiﬁcant changes in behaviour and appearance
including pilo-erection or comatose state.
2.2.2.3. Protocol 1 (screening test and efﬁcacy evaluation). The
screening test protocol is based upon the guidelines set out by the
European Plant Protection Organisation (EPPO), speciﬁcally
guidelines PP 1/113(2) (EPPO, 1998). For the testing of a novel
rodenticide; screening tests are suggested in which ﬁve male
laboratory strains of either Rattus norvegicus or Mus musculus are
used.
The procedure for the application of the transdermal rodenti-
cide was based upon the Organisation for Economic Co-operation
and Development (OECD) guidelines 434 (OECD, 2004) in which
the formulation is applied to a 10 cm2 area on the scruff of the
animal. Mortality and time until endpoint was recorded for each
formulation. Each formulation was dosed to 5 animals. A volume of
1 ml was dosed to each animal. While this protocol advises to shave
the area of application site these measures were not incorporated
in the current study as an ‘in-use’ application was preferred.
2.2.2.4. Data analysis. In order for a rodenticide to be considered
for rodent control it must be proven to be ‘sufﬁciently effective’.
100% mortality during screening is considered to be effective
(EPPO, 1998).
Animal distress was monitored 3 times daily during a 5 day
period, animals were then monitored 2 times per day for a further
9 days. Formulations which exhibit less than 100% mortality were
regardedas ineffective. The distress of the animalduring the protocol
was monitored using a distress scoring chart proposed byWolfensohn and Lloyd (2003), with amendments to enhance
description under provoked response.
Weight data was collected for all animals.
2.2.3. Statistical analysis
Statistical analysis of the in-vitro data was performed using a
one-way analysis of variance (ANOVA); this was to determine
statistical differences between the drug ﬂuxes determined for each
formulation. For the in-vivo data set one-way ANOVAs were
performed on the time till mortality and the average distress at
endpoint. In cases where ANOVA suggested signiﬁcant differences,
Tukey’s multiple comparison tests were performed between
formulations to determine the speciﬁc pairing in which differences
were observed. All one-way ANOVAs and Tukey multiple
comparisons were performed using GraphPad Prism version
6.00 for Windows, GraphPad Software (La Jolla California USA,
www.Graphpad.com). A probability, p < 0.1, was considered
signiﬁcant.
3. Results
3.1. Permeation results
3.1.1. Cellulose tubing in-vitro model
3.1.1.1. Chemical penetration enhancement. Cholecalciferol
permeation proﬁles using: DMSO, ethanol, oleic acid,
2-pyrrolidone and water as penetration enhancers were
obtained through cellulose tubing in an in-vitro model and are
illustrated in Fig.1. Fig. 2 shows the drug ﬂux comparisons between
the formulations tested. The 90/10 (v/v) DMSO/ethanol
(0.26  0.044 mg/cm2h) formulation was shown to signiﬁcantly
increase (p < 0.1) the drug ﬂux of cholecalciferol when compared to
the ethanol (0.14  0.008 mg/cm2h) and 2-pyrrolidone
(0.13  0.038 mg/cm2h) formulations. Based on these results, the
DMSO/ethanol co-solvent was selected for further investigations
as a penetration enhancer for cholecalciferol.
3.1.1.2. DMSO/ethanol co-solvent penetration enhancement. The
permeation proﬁles of cholecalciferol using DMSO/ethanol
co-solvents are shown in Fig. 3. The results suggest no
statistically signiﬁcant differences (one-way ANOVA, p < 0.1)
between the drug ﬂux of cholecalciferol with a DMSO/ethanol
co-solvent across the range 50/50 (v/v)–90/10 (v/v), respectively.
Fig. 4. Cholecalciferol permeation proﬁles obtained with the diffusion cell in-vitro
model. A volume of 5 ml was used for the donor phase. Dashed lines represent the
linear regression for the line of best ﬁt. Mean values  SD (n = 3).
Fig. 2. Drug ﬂux comparisons for chemical penetration enhancement of
cholecalciferol obtained with the cellulose tubing in-vitro model. Mean values  SD.
Signiﬁcant differences where indicated (p < 0.1, Tukey’s multiple comparison test)
(n = 3).
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3.1.2.1. Chemical penetration enhancement. Fig. 4 shows the
permeation of cholecalciferol through a synthetic membrane
using the diffusion cell arrangement. Based on the results from the
cellulose tubing in-vitro model, formulations containing high
percentages of DMSO were investigated, while ethanol
formulations served as comparators. A combination of
cholecalciferol concentrations and chemical penetration
enhancers were used.
The results suggest that for both cholecalciferol concentrations
(20% and 40% (w/v)) the ethanol (2.23  0.048 mg/cm2h and
6.62  0.44 mg/cm2h) formulations signiﬁcantly increased (p
< 0.1) drug ﬂux when compared with a DMSO/ethanol co-solvent
(1.19  0.078 mg/cm2h and 4.78  0.062 mg/cm2h). A summary of
cholecalciferol drug ﬂuxes obtained with each penetration
enhancer is contained in Table 1.
3.1.2.2. Dose response. Fig. 5 suggests the dose response
relationship as determined by the diffusion cell in-vitro model
A range of cholecalciferol concentrations were investigatedFig. 3. Cholecalciferol permeation proﬁles using DMSO/ethanol co-solvents
obtained with the cellulose tubing in-vitro model. All solutions contain 10% (w/
v) cholecalciferol released from a 1 ml volume. Mean values  SD (n = 3).comprising of 20%, 9%, 1.5% and 0.15% (w/v). The concentrations
were taken from the ﬁxed dose procedure for determining oral
toxicity (OECD guidelines 420) (OECD, 2001). The results suggest
that the 20% (w/v) cholecalciferol concentration (4.97  0.18 mg/
cm2h) produced a signiﬁcantly greater (p < 0.1) drug ﬂux when
compared to the other tested concentrations. A non linear
relationship was observed between formulation drug ﬂux
(mg/cm2h) plotted against cholecalciferol concentration (w/v%)
(y = 0.997 ln(x) + 1.49, r2 = 0.91, Microsoft Excel version 2003).
3.2. In-vivo results
Two in-vivo investigations were conducted: a screening
protocol, used to compare the range of penetration enhancers
and validate the in-vitro models, and an additional screening
protocol, used to determine if the favoured formulation was
‘sufﬁciently effective’ as deﬁned by the Regulation.
3.2.1. Protocol 1 (screening test)
A total of ﬁve formulations were implemented in the screening
protocol comparing penetration enhancers. These formulations
demonstrated high drug ﬂux when compared to other chemical
penetration enhancers during in-vitro investigations. Two of the
formulations used a DMSO/ethanol co-solvent, as indicated by the
cellulose tubing model; two of the formulations used ethanol as
indicated by the diffusion cell model while the remaining
formulation consisted of DMSO and oleic acid, as highlighted in
both in-vitro models. Two variations of cholecalciferol concentra-
tion were implemented; 40% (w/v) in ethanol and 70/30 (v/v)
DMSO/ethanol co-solvent, while 20% (w/v) was used with ethanol,
90/10 (v/v) DMSO/ethanol and 90/10 (v/v) DMSO/oleic acid. A
thickening agent (methyl cellulose) was added to all formulations
containing DMSO, 1% (w/v) was added to the 90/10 (v/v)
DMSO/ethanol and the 70/30 (v/v) DMSO/ethanol formulations,
while 0.75% (w/v) was added to the 90/10 (v/v) DMSO/oleic acid
formulation.
Fig. 6 shows the respective survival rates for each of the ﬁve
formulations designed to improve the transport of cholecalciferol
through rat skin. The results suggest that only formulations which
Table 1
Formulation parameters and drug ﬂux. Drug ﬂux quoted as mean values  SD (n = 3).
Cholecalciferol concentration %
(w/v)
Solvent Diffusion area
(cm2)
Drug ﬂux (Js) (mg/
cm2h)
In-vitro model: cellulose tubing
Comparison of chemical penetration
enhancers
10 90/10 (v/v) DMSO/ethanol 40 0.26  0.044
10 90/10 (v/v) DMSO/oleic acid 40 0.18  0.038
10 90/10 (v/v) ethanol/water 40 0.17  0.047
10 Ethanol 40 0.14  0.008
10 2-pyrrolidone 40 0.13  0.038
DMSO/ethanol co-solvent penetration
enhancement
10 70/30 (v/v) DMSO/ethanol 40 0.23  0.027
10 90/10 (v/v) DMSO/ethanol 40 0.22  0.049
10 80/20 (v/v) DMSO/ethanol 40 0.19  0.03
10 50/50 (v/v) DMSO/ethanol 40 0.18  0.025
10 60/40 (v/v) DMSO/ethanol 40 0.16  0.054
In-vitro model: diffusion cell
Comparison of chemical penetration
enhancers
40 Ethanol 2.54 6.62  0.44
40 90/10 (v/v) DMSO/ethanol 2.54 4.78  0.062
20 90/10 (v/v) DMSO/oleic acid 2.54 3.5  0.15
20 Ethanol 2.54 2.23  0.048
20 90/10 (v/v) DMSO/ethanol 2.54 1.19  0.078
Dose–response 20 50/50 (v/v) DMSO/ethanol 15% (v/v) PEG
200
2.54 4.97  0.18
9 50/50 (v/v) DMSO/ethanol 15% (v/v) PEG
200
2.54 3.14  0.18
1.5 50/50 (v/v) DMSO/ethanol 15% (v/v) PEG
200
2.54 0.84  0.037
0.15 50/50 (v/v) DMSO/ethanol 15% (v/v) PEG
200
2.54 0.09  0.018
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guidelines these formulations can be considered for further
investigation. The ethanol formulations containing 20% and 40%
(w/v) cholecalciferol caused 20% and 60% mortality, respectively;
these formulations would be ineffective as a rodenticide and
warranted no further investigation. The results suggest that the
inclusion of DMSO has improved the penetration of cholecalciferolFig. 5. Cholecalciferol permeation proﬁles using varied concentrations of
cholecalciferol obtained with the diffusion cell in-vitro model. A total of 5 ml
was added to each donor chamber. All formulations had the indicated amount of
cholecalciferol in a formulation consisting of 15% (v/v PEG 200) made up to volume
using a 50/50 co-solvent of DMSO/ethanol. Mean values  SD (n = 3).causing 100% mortality within 5 days of application when
compared with the ethanol formulations. No signiﬁcant differ-
ences (p < 0.1) were found between the times taken for mortality
across the three formulations that exhibited 100% mortality.
Fig. 7 shows the quantiﬁcation of distress as obtained with the
distress scoring chart. The results suggest the average distress at
the endpoint ranged between 5 and 10, apart from the 20% (w/v)
cholecalciferol in ethanol which had an average distress of 2;
however this formulation only produced 20% mortality. No
signiﬁcant differences (p < 0.1) in distress at endpoint were
observed between formulations which caused 100% mortality.
The results suggest that only moderate changes in behaviour are
exhibited by a rodent prior to mortality including a reduction in
mobility and a reduced food and water intake.
3.2.2. Protocol 1 (efﬁcacy evaluation)
An additional formulation was used for the determination of
efﬁcacy consisting of 50/50 DMSO/ethanol, 15% (w/v) PEG 200 and
20% (w/v) cholecalciferol. A negative control was also employed
consisting of 15% (v/v) PEG 200 in a 50/50 DMSO/ethanol
co-solvent. The co-solvent penetration enhancer of DMSO/ethanol
was used as the result from the screening protocol suggested that
this formulation warranted further investigation. The addition of
PEG 200 to the formulation was designed to thicken the
formulation and aid in adherence to the unprepared coat of a
rat. A 50/50 (v/v) DMSO co-solvent also provided improved
physical properties when compared to the 90/10 (v/v)
DMSO/ethanol co-solvent speciﬁcally a reduced freezing point.
Fig. 8shows the survival analysis of the efﬁcacy screening
evaluation. A 100% mortality was achieved with a 50/50 DMSO/
ethanol, 15% (w/v) PEG 200 and 20% (w/v) cholecalciferol formula-
tion suggesting that the formulation would be sufﬁciently effective
for consideration as a rodenticide. The formulation also exhibited a
Fig. 6. Mortality and time until endpoint summary for formulations. (A–E) Survival rates for transdermal cholecalciferol formulations. Mean values  SD (n = 5).
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solvents dosed in the screening protocol (90/10 (v/v) DMSO/ethanol
20% (w/v) cholecalciferol = 84 h  25 h, 50/50 (v/v) DMSO/ethanol
20% (w/v) cholecalciferol = 64 h  22 h). The negative control did not
yield any fatalities thus it can be concluded that the cholecalciferol is
responsible for the lethal action.
Fig. 9 shows the distress scoring chart and animal weight for the
efﬁcacy evaluation and negative control. The negative control
showed no changes in behaviour, coupled with an increase in
weight suggesting that food and water intake was healthy. The 20%
(w/v) cholecalciferol concentration exhibited signiﬁcant changes
in behaviour, however only minor changes were observed during
the ﬁrst day followed by a quick increase in distress as recorded
within the distress scoring chart.
4. Discussion
When evaluating rodenticidal formulations, the European
Union requests in-vivo data in the form of screening tests, efﬁcacy
evaluations and ﬁeld trials; however, in-vitro data plays a vital rolein determining appropriate formulations to take forward into these
tests.
In this research two in-vitro models were used to compare
formulations developed internally with those previously
speculated. A drug ﬂux of 0.26  0.044 mg/cm2h was determined
for cholecalciferol dosed in a DMSO/ethanol co-solvent (10% (w/v)
cholecalciferol) by using a cellulose tubing model. The ethanol
formulation proposed by Agnew (2010, 2011) produced a
lower drug ﬂux of 0.13  0.0038 mg/cm2h (10% (w/v) cholecalcifer-
ol) (Fig. 2). The opposite was observed when these formulations
were tested using the diffusion cell model (Fig. 4), the model
suggested higher drug ﬂux for ethanol formulations when
compared to DMSO/ethanol co-solvent over two cholecalciferol
concentrations (Table 1). All penetration enhancers tested with
both models showed inﬂated drug ﬂuxes when evaluated with the
diffusion cell model.
The most notable differences between the in-vitro models is
increased concentration of the solute in the diffusion cell
formulations and the absence of donor phase stirring in the
cellulose tubing model, potentially leading to a static solvent layer
Fig. 7. Average distress at mortality. (A–E) Formulation humaneness as recorded with the distress scoring chart. Mean values  SD (n = 5).
Fig. 8. Survival analysis for the efﬁcacy evaluation screening test on formulation:
20% (w/v) cholecalciferol and 15% (v/v) PEG 200 in 50/50 (v/v) DMSO/ethanol (n = 5).
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thus takes the form of a multilayer arrangement which can be
described mathematically as (Martin and Bustamante, 1993):
Js ¼
1
A
dM
dt
 
¼ DmKDaC1
hmDa þ 2haDmK
In which Dm and Da are the membrane and static layer diffusivities,
respectively, and K represents the partition coefﬁcient. It can also
be seen that the concentration of the solute in the donor phase C1,
membrane thickness hm and the static diffusion layer thickness ha
all contribute to the drug ﬂux calculation. Fundamentally, an
increase in solute concentration in the donor phase will increase
ﬂux, while an increase in the thicknesses of the membrane and
static diffusion layer will decrease ﬂux. The static diffusion layer
thickness ha is a physical property and is proportional to the
amount of agitation (Martin and Bustamante, 1993), greater
stirring reduces ha promoting higher ﬂuxes which can be seen
when comparing the two in-vivo models in this research.
Fig. 9. Formulation humaneness as recorded with the distress scoring chart and
weight. Mean values  SD (n = 5). Formulations contained indicated amounts of
cholecalciferol in 50/50 (v/v) DMSO/ethanol co-solvent containing 15% (v/v) PEG
200.
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to disrupt static diffusion layers than the ethanol solvent system.
Molecular interaction of the co-solvent could be thought to be
further enhancing dissolved solute movement in the donor phase.
This action could be likened to the increase in solubility of
components through molecular interactions of co-solvents.
The screening protocol served to both compare DMSO
co-solvents with ethanol formulations and determine whether
these formulations warranted further investigations. Ethanol
formulations containing 20% and 40% (w/v) cholecalciferol
exhibited 20% and 60% mortality, respectively, during the
screening protocol; while all formulations containing DMSO
displayed 100% mortality (Fig. 6). In line with the EPPO guidelines
(EPPO, 1998) the ethanol based formulations would not be
considered for use as a rodenticide as they do not produce
sufﬁcient mortality. The difference between these investigations
and that of Agnew (2010, 2011) may lie in the origin of the rodent.
In this study, Sprague-Dawley rodents were used with weights
between 250 and 350 g whereas a wild Norway rat of unknownweight was used in Agnew’s work. Potential differences in weight
may have resulted in the more potent dose during Agnew’s own
study.
A second in-vivo screening test was employed to further
investigate a DMSO/ethanol co-solvent with a reduced level of
DMSO as the in-vitro investigations suggested no signiﬁcant
difference in drug ﬂux when the ratio of DMSO/ethanol was varied
(Fig. 3). A negative control, containing no cholecalciferol, was also
employed during this study to conﬁrm that mortality could be
attributed to the cholecalciferol. The 20% (w/v) cholecalciferol
concentration in 50/50 DMSO/ethanol and 15% (v/v) PEG
200 resulted in 100% mortality suggesting that this concentration
would be sufﬁciently effective for further regulatory trials. The 1 ml
dose produced 100% mortality in 64.4 h  22 h; quicker than that
found in the previous screening study (Figs. 6 and 8). No adverse
effects were seen in the animals dosed with the negative control.
The in-vivo responses correlated better with the cellulose
tubing in-vitro model suggesting formulations applied direct to the
fur of rats skin display absorption controlled by a static diffusion
layer. DMSO and oleic acid have not been previously tested with
cholecalciferol, they have however, been shown to improve
penetration (Williams and Barry, 2012) of compounds such as
anti-inﬂammatory drugs (Gwak and Chun, 2002; Larrucea et al.,
2001; Meshulam et al., 1993; Moreira et al., 2010). While DMSO is
proven to disrupt the dermis it is not typically used as it causes an
unpleasant taste in the mouth of humans and has long lasting
effects on the area of skin to which it is applied. In the context of its
use as a rodenticide these would be disregarded. In this regard,
both permeation studies and in-vivo results suggest that a DMSO/
ethanol co-solvent is the most effective penetration enhancer
investigated for use in combination with cholecalciferol.
The results suggest that transdermal delivery of cholecalciferol
has the potential to provide an alternative to anticoagulant baiting
methods. Whilebaiting approaches havebeen usedsuccessfully they
depend on the rodent ingesting lethal amounts of the bait. This
ingestionisnotguaranteedandisacontributortothedevelopmentof
anticoagulant resistance (Quy et al., 1992). A one dose transdermal
application is the most efﬁcient manner inwhichto deliver the toxin;
with an optimised ‘minimum’ dose been administered reducing the
waste and any unnecessary environmental exposure. The difﬁculty
associated with direct application of a rodenticide have been
discussed and details for successful deployment provided elsewhere
(Goode, 2010). Transdermal delivery of cholecalciferol is a feasible
alternativetoanticoagulantbaits,howeverlargerefﬁcacyevaluations
are required to produce statistically signiﬁcant data for the European
Union as well as proof of this formulations effectiveness in the ﬁeld.
5. Conclusions
A suitable chemical penetration enhancer to facilitate trans-
dermal delivery of relatively low levels of cholecalciferol has been
found.
Through both in-vitro and in-vivo investigations a 1 ml dose of
50/50 (v/v) DMSO/ethanol, 15% (v/v) PEG 200 vehicle containing
20% (w/v) cholecalciferol has been proven to be sufﬁciently
effective as a rodenticide (Regulation No. 528/2012). This dose was
found to cause 100% mortality in 64.4 h  22 h.
Two in-vitro models have been developed to screen potential
formulations. The cellulose tubing model has correlated with
in-vivo investigations of rat skin suggesting that future work
should consider the use of static diffusion layers in modelling
formulations of this type.
Transdermal delivery of cholecalciferol has been shown to be
sufﬁciently effective in screening studies, thus offering an
alternative to anticoagulant baits that differs in both active
ingredient and the manner of its controlled delivery.
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